UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 352

Sortiert nach

Extended-Spectrum β-Lactamases and Clinical Outcomes: Current Data

Clinical infectious diseases, 2006-04, Vol.42 (Supplement-4), p.S164-S172

2006

Volltextzugriff (PDF)

Pharmacokinetics-Pharmacodynamics of Antimicrobial Therapy: It's Not Just for Mice Anymore

Clinical infectious diseases, 2007-01, Vol.44 (1), p.79-86

2007

Volltextzugriff (PDF)

Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis

Clinical infectious diseases, 2010-06, Vol.50 (12), p.1568-1574

2010

Volltextzugriff (PDF)

Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

Antimicrobial agents and chemotherapy, 2019-08, Vol.63 (8)

2019

Volltextzugriff (PDF)

Antimicrobial Safety: Focus on Fluoroquinolones

Clinical infectious diseases, 2005-07, Vol.41 (Supplement-2), p.S144-S157

2005

Volltextzugriff (PDF)

Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)

Antimicrobial agents and chemotherapy, 2020-01, Vol.64 (2)

2020

Volltextzugriff (PDF)

Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally

Clinical infectious diseases, 2007-09, Vol.45 (6), p.753-760

2007

Volltextzugriff (PDF)

Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective

Drug resistance updates, 2011-04, Vol.14 (2), p.107-117

2011

Volltextzugriff (PDF)

The Pharmacokinetic and Pharmacodynamic Profile of Tigecycline

Clinical infectious diseases, 2005-09, Vol.41 (Supplement-5), p.S333-S340

2005

Volltextzugriff (PDF)

Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations

Antimicrobial agents and chemotherapy, 2016-03, Vol.60 (3), p.1600-1607

2016

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Considerations in the Design of Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia Studies: Look before You Leap

Clinical infectious diseases, 2010-08, Vol.51 (Supplement-1), p.S103-S110

2010

Volltextzugriff (PDF)

Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with Tigecycline

Antimicrobial Agents and Chemotherapy, 2012-02, Vol.56 (2), p.1065-1072

2012

Volltextzugriff (PDF)

Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia

Antimicrobial Agents and Chemotherapy, 2011-05, Vol.55 (5), p.2113-2121

2011

Volltextzugriff (PDF)

Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane

Antimicrobial Agents and Chemotherapy, 2013-12, Vol.57 (12), p.5924-5930

2013

Volltextzugriff (PDF)

Randomized Pharmacokinetic and Pharmacodynamic Comparison of Fluoroquinolones for Tuberculous Meningitis

Antimicrobial Agents and Chemotherapy, 2011-07, Vol.55 (7), p.3244-3253

2011

Volltextzugriff (PDF)

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model

Antimicrobial Agents and Chemotherapy, 2013-06, Vol.57 (6), p.2809-2814

2013

Volltextzugriff (PDF)

Antibacterial drug development program successes and failures: a pharmacometric explanation

Current opinion in pharmacology, 2017-10, Vol.36, p.1-7

Ambrose, Paul G

2017

Volltextzugriff (PDF)

Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations

Antimicrobial Agents and Chemotherapy, 2007-07, Vol.51 (7), p.2329-2336

2007

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infection

Antimicrobial Agents and Chemotherapy, 2009-09, Vol.53 (9), p.3847-3854

2009

Volltextzugriff (PDF)

Relationship between Ceftolozane-Tazobactam Exposure and Drug Resistance Amplification in a Hollow-Fiber Infection Model

Antimicrobial Agents and Chemotherapy, 2013-09, Vol.57 (9), p.4134-4138

2013

Volltextzugriff (PDF)

Population Pharmacokinetics of Fusidic Acid: Rationale for Front-Loaded Dosing Regimens Due to Autoinhibition of Clearance

Antimicrobial Agents and Chemotherapy, 2013-01, Vol.57 (1), p.498-507

2013

Volltextzugriff (PDF)

Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia

Antimicrobial Agents and Chemotherapy, 2012, Vol.56 (1), p.130-136

2012

Volltextzugriff (PDF)

Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia

Antimicrobial Agents and Chemotherapy, 2009-10, Vol.53 (10), p.4422-4428

2009

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Evaluate In Vitro Susceptibility Test Interpretive Criteria for Ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy, 2014-02, Vol.58 (2), p.885-891

2014

Volltextzugriff (PDF)

Isoniazid's Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion of Mycobacterium tuberculosis in the Log Phase of Growth

The Journal of infectious diseases, 2007-01, Vol.195 (2), p.194-201

2007

Volltextzugriff (PDF)

1 – 25 von 352

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(338)
Mit Volltextzugriff
(332)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(235)
Life Sciences & Biomedicine
(220)
Humans
(141)
Microbiology
(127)
Pharmacology & Pharmacy
(95)
Biological And Medical Sciences
(91)
Infectious Diseases
(87)
Medical Sciences
(81)
Female
(65)
Male
(60)
Microbial Sensitivity Tests
(59)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(51)
Pharmacology. Drug Treatments
(51)
Anti-Bacterial Agents - Pharmacokinetics
(46)
Pharmacology
(46)
Immunology
(43)
Anti-Bacterial Agents - Pharmacology
(41)
Middle Aged
(41)
Adult
(40)
Animals
(39)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Extended-Spectrum β-Lactamases and Clinical Outcomes: Current Data

Pharmacokinetics-Pharmacodynamics of Antimicrobial Therapy: It's Not Just for Mice Anymore

Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis

Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

Antimicrobial Safety: Focus on Fluoroquinolones

Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)

Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally

Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective

The Pharmacokinetic and Pharmacodynamic Profile of Tigecycline

Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations

Pharmacokinetic-Pharmacodynamic Considerations in the Design of Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia Studies: Look before You Leap

Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with Tigecycline

Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia

Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane

Randomized Pharmacokinetic and Pharmacodynamic Comparison of Fluoroquinolones for Tuberculous Meningitis

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model

Antibacterial drug development program successes and failures: a pharmacometric explanation

Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations

Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infection

Relationship between Ceftolozane-Tazobactam Exposure and Drug Resistance Amplification in a Hollow-Fiber Infection Model

Population Pharmacokinetics of Fusidic Acid: Rationale for Front-Loaded Dosing Regimens Due to Autoinhibition of Clearance

Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia

Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Evaluate In Vitro Susceptibility Test Interpretive Criteria for Ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae

Isoniazid's Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion of Mycobacterium tuberculosis in the Log Phase of Growth

Suchergebnisse filtern